The global monoclonal antibodies (mabs) market was valued at about $135.38 billion in 2018 and is expected to grow to $212.64 billion at a CAGR of 12.0% through 2022. North America was the largest region in the monoclonal antibodies market. In 2018, followed by Europe, Asia Pacific and Middle East respectively. This region is expected to remain the largest during the next five years. The monoclonal antibodies market in Middle East is forecasted to register the highest CAGR during 2018-2023.